доступа: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryin
formation/guidances/ucm070640.pdf.
315. Guidance for Industry. SUPAC–MR: Modified Release Solid Oral
Dosage Forms. Scale–Up and Postapproval Changes: Chemistry, Manufacturing,
and
Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence
Documentation [Электронный ресурс] // Food and Drug administration. – 1997.
– Режим доступа: https://www.fda.gov/regulatory-information/search-fda-
guidance-documents/supac-mr-modified-release-solid-oral-dosage-forms-scale-
and-postapproval-changes-chemistry.
316. Guidance for Industry. SUPAC-SS: Nonsterile Semisolid Dosage Forms.
Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls.
In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation [Элек-
тронный ресурс]// Food and Drug administration. – 1997. – Режим доступа:
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/
supac-ss-nonsterile-semisolid-dosage-forms-scale-and-post-approval-changes–
chemistry-manufacturing.
317. Guidance for Industry. PAT – A Framework for Innovative Pharmaceutical
Development, Manufacturing, and Quality Assurance [Электронный ресурс]
// Food and Drug administration. – 2004. – Режим доступа: https://www.fda.
gov/regulatory–information/search-fda-guidance-documents/pat-framework-
innovative-pharmaceutical-development-manufacturing-and-quality-assurance.
318. Guidance for Industry. Process Validation:
General Principles and
Practices. Revision 1 [Электронный ресурс]// Food and Drug Administration.
CGMP. – 2011. – Режим доступа: www.fda.gov/downloads/Drugs/GuidanceCo
mplianceRegulatoryInformation/Guidances/UCM070336.pdf.
319. Guidance for Industry. Waiver of In Vivo Bioavailability and
Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based
on Biopharmaceutics Classification System [Электронный ресурс]// Food and
Drug administration. –2000. – Режим доступа: http://www.fda.gov/downloads/
Drugs/Guidances/ucm070246.
320. Guidance on the investigation of bioequivalence. CPMP/EWP/
QWP/1401/98 Rev. 1 [Электронный ресурс]// European Medicines Agency.
Сommittee for Medical Products of Human use. – 2010. – Режим доступа:
ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/
WC500070039.pdf.
321. Guideline on bioanalytical method validation. EMEA/CHMP/
EWP/192217/2009 Rev. 1 [Электронный ресурс] //
European Medicines
Agency. Сommittee for Medical Products of Human use. – 2010. – Режим до-
ступа:
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_
guideline/2011/08/WC500109686.pdf.
322. Guideline on Plastic Immediate Packaging Materials. CPMP/
QWP/4359/03, EMEA/CVMP/205/ 04. [Электронный ресурс] // European
Medicines Agency. Сommittee for Medical Products of Human use. – 2005. –
Режим доступа: https://www.ema.europa.eu/en/documents/scientific-guideline/
guideline-plastic-immediate-packaging-materials_en.pdf.
323. Guideline on the pharmacokinetic and clinical evaluation of modified
release dosage forms (EMA/CPMP/EWP/280/96 Corr1) [Электронный ресурс]
Список литературы
379
// European Medicines Agency. Сommittee for Medical Products of Human
use. – 2013. – Режим доступа: www.ema.europa.eu/en/ documents/scientific–
guideline/draft-guideline-pharmacokinetic-clinical-evaluation-modified–release-
dosage-forms_en.pdf.
324. Guideline on Excipients in the Dossier for Application
for Marketing
Authorisation of a Medicinal Product. EMEA/CHMP/QWP/396951/2006
[Электронный ресурс]// European Medicines Agency. Сommittee for Medical
Products of Human use. – 2007. – Режим доступа: www.ema.europa.eu/
en/documents/scientific-guideline/guideline-excipients-dossier-application-
marketing–authorisation-medicinal-product-revision-2_en.pdf.
325. Guideline on pharmaceutical development of medicines for paediatric
use. EMA/CHMP/QWP/805880/2012 Rev. 2 [Электронный ресурс] // European
Medicines Agency. Сommittee for Medical Products of Human use. – 2013. – Ре-
жим доступа: www.ema.europa.eu/en/documents/scientific-guideline/guideline-
pharmaceutical-development-medicines-paediatric-use_en.pdf.
326.
Gupta, M
. Docking techniques in pharmacology: How much promising?
[Текст] / M. Gupta, R. Sharma, A. Kumar //
Computational Biology and
Chemistry. – 2018. – V. 76. – p. 210–217.
327.
Halgren, T.A
. Identifying and characterizing binding sites and assessing
druggability [Текст] / T. A. Halgren // Journal of Chemical Information and
Modeling. – 2009. – V. 49, №2. – р. 377–389
328.
Hansch, C
. Correlation of biological activity of phenoxyacetic acid with
Hammet constants and partition coefficients [Текст] / C. Hansch, P. Maloney,
T. Fujita // Nature. – 1962. – V. 194. – p. 178–180.
329.
Hansch, С
. Exploring QSAR: Hydrophobic, electronic, steric constants
[Текст] / С. Hansch, A. Leo, D. Hoekman. – Oxford: Oxford University Press,
1995.
330.
Hancsh, C
. Quantitative structure activity relationships and the unnamed
science [Текст] / C. Hancsh // Accounts of Chemical Research. – 1993. – V. 26.
– p. 147–153.
331.
Hancsh, C
. Ro – sigma – pi analysis. A method for the correlation of
biological activity and chemical structure [Текст] / C. Hancsh, T. Fujita // Journal
of the American Chemical Society. – 1964. – V. 86. – p. 1616–1626.
332.
Hobday, M
. Innovation in East Asia: The Challenge to Japan [Текст]. –
Aldershot:
Edward Elgar, 1995. – 224 p.
333.
Hopkins, A.L
. Network pharmacology: the next paradigm in drug
discovery [Текст] / A.L. Hopkins // Nature Chemical Biology. – 2008. – V. 11,
№4. – р. 682–690.
334.
Hopkins, A.L
. Network pharmacology [Текст] / A.L. Hopkins // Nature
Biotechnology. – 2017. – V. 25, №10. – p. 1110–1111.
335.
Hopkins, A.L
. Target analysis: a priori assessment of druggability [Текст]
/ A.L. Hopkins, C.R. Groom // Ernst Schering Research Foundation workshop. –
2003. –V. 42. – p. 11–17.
336.
Horwath, D
. Quantitative structure–activity relationships: in silico
chemistry or high tech alchemy? [Текст]/ D. Horwath // Revue Roumaine de
Chimie. – 2010. –V. 55, №11–12. – р. 783–801.
380
Достарыңызбен бөлісу: